Tirzepatide is the only approved molecule in this class that targets two incretin receptors. Below are the trial numbers that matter, with their exact basis, followed by the compounded market and its regulatory problems.
| Trial | Who | Comparison and length | Result |
|---|---|---|---|
| SURMOUNT-1 | 2,539 adults with obesity or overweight, no diabetes | 5, 10, 15 mg vs placebo, 72 weeks | Mean weight change -15.0%, -19.5%, -20.9% vs -3.1% (treatment-regimen estimand) |
| SURMOUNT-5 | 751 adults with obesity, no diabetes | Tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, open label, 72 weeks | -20.2% vs -13.7%; waist -18.4 cm vs -13.0 cm |
| Zepbound OSA studies | 469 adults with obesity and moderate-to-severe sleep apnea | 10 or 15 mg vs placebo, 52 weeks | Significant fall in apnea-hypopnea index vs placebo (basis of the OSA approval) |
| SURPASS-2 | 1,879 adults with type 2 diabetes on metformin | 5, 10, 15 mg vs semaglutide 1 mg, 40 weeks | HbA1c -2.0 to -2.3 points vs -1.9; weight -7.6 to -11.2 kg vs -5.7 kg |
| SURPASS-CVOT | 13,299 adults with type 2 diabetes and heart disease | Up to 15 mg vs dulaglutide 1.5 mg, median 210.1 weeks | Non-inferior on major CV events (HR 0.92; 95.3% CI 0.83 to 1.01) |
The 20.9% figure from SURMOUNT-1 counts everyone randomized, including people who stopped the drug. It is a group mean, not a typical or guaranteed result. Fuller summaries are on our SURMOUNT results page.
What makes tirzepatide different from semaglutide?
Tirzepatide binds two receptors, GIP and GLP-1; semaglutide binds only GLP-1. The Zepbound label calls tirzepatide "a GIP receptor and GLP-1 receptor agonist."
The label says GLP-1 regulates appetite and calorie intake, and that nonclinical studies suggest adding GIP may contribute further. That is a careful statement: the label does not claim the second receptor explains the larger weight change. What we do have is a head-to-head trial. In SURMOUNT-5, adults without diabetes lost a mean 20.2% on tirzepatide versus 13.7% on semaglutide at 72 weeks. The trial was open label and funded by Lilly, which makes tirzepatide.
Which brands contain tirzepatide?
Two FDA-approved brands, both from Lilly, both once-weekly injections from 2.5 mg to 15 mg.
- Zepbound: weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity. Approved November 8, 2023.
- Mounjaro: type 2 diabetes in adults and children 10 and older, plus cardiovascular risk reduction in high-risk adults with type 2 diabetes. Approved May 13, 2022.
Under both labels, treatment starts at 2.5 mg and climbs in 2.5 mg steps at least 4 weeks apart, with 15 mg as the adult maximum. Both labels list a single-dose pen, single-dose vial, multi-dose vial and KwikPen. Both carry a boxed warning for thyroid C-cell tumors seen in rats, with a contraindication for people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Drugs@FDA showed no generic tirzepatide, final or tentative, when we checked on November 8, 2026.
How much does compounded tirzepatide cost?
Across 24 compounded tirzepatide programs in our price table, the lowest all-in monthly figure per program ran from $69 to $299, with a median of $149.
That figure folds in any membership (annual fees divided by 12) at a standard injectable dose. The reads come from each program's own pages and are dated October 15, 2026, except NexLife's, dated November 6, 2026, so the dates are mixed. The bottom of the range is a sticker that depends on a $199 yearly membership; several others depend on sales or prepaid terms. See the price index for each program and its conditions.
For scale, Lilly's self-pay Zepbound KwikPen, read October 15, 2026, cost $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg to 15 mg with refills within 45 days. Those savings end December 31, 2026.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is made with the drug in Zepbound, but it is not the same product, and FDA does not review it for safety, effectiveness or quality before sale, per FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026.
A 503A pharmacy may compound it for an individual patient's prescription. Large-batch 503B production is a separate question: on April 30, 2026, FDA proposed not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list. The comment period ran to July 30, 2026, and we found no final decision as of November 20, 2026. FDA's page also says compounded multi-dose vials should be discarded 28 days after first use.
What did FDA's Empower warning letter say?
FDA sent warning letter 738238 to Empower Clinic Services, LLC, doing business as Empower Pharmacy, dated September 18, 2026 and posted September 22, 2026. The letter said its compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products," and it cited insanitary conditions.
The add-in ingredient was central. In this letter, FDA treated the vitamin-added versions as essentially copies of the approved drugs, so the added vitamin did not make them different products in the agency's reading. A warning letter is FDA's position, not a court finding, and the company can respond. If a program advertises tirzepatide "with" a vitamin as a selling point, treat that as a question to ask, not a reassurance.
How do you check a compounded tirzepatide program?
Ask for the dispensing pharmacy's name and state, confirm its license, and get the all-in price at the dose you will reach, not the starter dose. Read the cancellation terms before paying. Our compounded tirzepatide checklist lists the questions in order.
Frequently asked questions
Is tirzepatide stronger than semaglutide?
In the one head-to-head obesity trial, SURMOUNT-5, adults without diabetes on maximum tolerated tirzepatide (10 or 15 mg) lost a mean 20.2% of body weight at 72 weeks, versus 13.7% on semaglutide (1.7 or 2.4 mg). The trial was open label and Lilly-funded. Gastrointestinal effects were the most common adverse events in both groups, mostly mild to moderate.
What does the treatment-regimen estimand mean?
It is a way of analyzing a trial that counts every randomized participant, whether or not they kept taking the drug. SURMOUNT-1's 20.9% mean weight reduction at 15 mg uses that approach, so it reflects real-world-style dropouts. Analyses that look only at people who stayed on treatment usually report larger numbers, so always check which estimand a figure uses.
What is the median price of compounded tirzepatide?
Across the 24 compounded tirzepatide programs in our price table, the median of each program's lowest all-in monthly figure was $144, in a range of $69 to $299. Reads are dated October 15, 2026, except NexLife's, dated November 6, 2026. The lowest figures often depend on a membership, a sale or a prepaid plan.
Why did FDA warn Empower Pharmacy?
FDA's warning letter 738238, dated September 18, 2026, said Empower's compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin appeared to be essentially copies of FDA-approved semaglutide and tirzepatide products, and cited insanitary conditions. The letter is an FDA allegation that the company can respond to; it is not a court ruling.
Is there a generic tirzepatide?
No. When we checked Drugs@FDA on November 8, 2026, the only tirzepatide applications listed were Lilly's Zepbound and Mounjaro, with no generic approval or tentative approval. Compounded tirzepatide sold through telehealth programs is not a generic; it is not FDA-approved and is not the same product as either brand.
Can tirzepatide be used for sleep apnea?
Yes, as Zepbound. FDA approved Zepbound on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on two 52-week trials in 469 adults without type 2 diabetes. The label's maintenance dose for that use is 10 mg or 15 mg weekly. Medicare's GLP-1 Bridge excludes people with moderate-to-severe sleep apnea.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216 — published July 21, 2022; abstract read 2026-11-08
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36 — published July 3, 2025; abstract read 2026-11-08
- FDA labels (DailyMed): Zepbound and Mounjaro prescribing information — Zepbound revised 08/2026; Mounjaro revised August 2026; sections 1, 3, 12.1, 14 read 2026-11-08
- FDA: Warning letter 738238, Empower Clinic Services, LLC dba Empower Pharmacy — dated 2026-09-18, posted 2026-09-22 (facts file)
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss — content current as of 10/01/2026; read 2026-11-08
- FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list — announced 2026-04-30; no final decision found as of 2026-10-15
- Lilly: LillyDirect Zepbound self-pay terms — read 2026-10-15
Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.
Check NexLife's plans and state availability → See the price index